ArticleDiscover oncology2026
LncRNA MCM3AP-AS1 is a potential prognostic marker for osteosarcoma and promotes its development by targeting miR-205-5p.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma (OS) is one of the more common malignant tumors, with a poor prognosis for patients that seriously affects their quality of life.
objectivesThis study examined the relationship between MCM3AP-AS1 and the severity and prognosis of OS patients, and investigated its impact on OS progression by targeting miR-205-5p.
methodsQuantitative PCR to detect the expression of MCM3AP-AS1 and miR-205-5p in OS tissues and cells. The clinical relevance of MCM3AP-AS1 was analyzed using a Chi-square test. Risk factors related to poor prognosis and recurrence-free survival rate were analyzed using the Cox risk model and the K–M curve. The dual luciferase assay and/or RIP assay were performed to confirm the targeting relationship between MCM3AP-AS1 and miR-205-5p, as well as YAP1 and miR-205-5p. The impact of MCM3AP-AS1 targeting miR-205-5p/YAP1 axis on OS progression was analyzed using CCK-8 and Transwell functional experiments.
resultsMCM3AP-AS1 was significantly increased in OS tissues/cells, correlating with adverse clinicopathological features and poor prognosis. miR-205-5p was down-regulated and negatively correlated with MCM3AP-AS1. Dual luciferase reporter and/or RIP assays confirmed that MCM3AP-AS1 directly targeted miR-205-5p, and miR-205-5p directly bound to the 3’UTR of YAP1. Silencing MCM3AP-AS1 inhibited OS cell functions, while reducing mRNA and protein expression of YAP1. Co-inhibiting miR-205-5p reversed these effects and restored YAP1 expression. Triple intervention reversed the promotion of cell malignant behaviors induced by dual intervention.
conclusionMCM3AP-AS1 promotes OS via sponging miR-205-5p/YAP1 axis, serving as a potential prognostic marker and candidate therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.